TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02348307
Drug: Placebo, (Oral single dosing)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo arm receive placebo.
Study: NCT00565955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive placebo tablets.
Study: NCT02602509
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03941444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution
Study: NCT03874234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
Study: NCT00087295
Drug: Depsipeptide
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
Study: NCT03026803
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00559338
Drug: recombinant B-type, natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
Study: NCT00559338
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
Study: NCT03802721
Drug: [14C]-benzo[a]pyrene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micro-dose (50 ng) (5.4 nCi)
Study: NCT02976831
Drug: AZD0284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution, concentration: 2 mg/mL and 15 mg/mL
Study: NCT02976831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching AZD0284 in the form of an oral solution with water.
Study: NCT00506389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
Study: NCT01057628
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03715465
Drug: Melatonin 0.5 MG
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin tablet
Study: NCT03815292
Drug: MMH-MAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03815292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00702624
Drug: placebo-recFSH (follitropin beta)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
Study: NCT02506777
Drug: Fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02506777
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02506777
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02506777
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00469508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg pills taken orally daily for 12 wks
Study: NCT03561779
Drug: YYD302 2ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: YYD302 2ml
Study: NCT03561779
Drug: Active comparator: Synovian Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator: Synovian Inj.
Study: NCT02974361
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02974361
Drug: Ibuprofen-LDH
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02406144
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04134897
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2, bid, per os, days 1-14, 4 cycles
Study: NCT04134897
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
Study: NCT01229228
Drug: Naproxen Test
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-mg single dose
Study: NCT01229228
Drug: Naproxen Test
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400-mg (2 x 200-mg)
Study: NCT01229228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00189085
Drug: simvastatin and ezetimibe
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01699997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray with placebo solution
Study: NCT00996840
Drug: SB-681323 Intravenous 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg SB-681323 Intravenous administration infused over 24 hours
Study: NCT00996840
Drug: SB-681323 Intravenous 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg SB-681323 Intravenous administration infused over 4 hours
Study: NCT01973283
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
Study: NCT03467620
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one oral placebo capsule daily for a duration of 12 weeks
Study: NCT02872103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
Study: NCT02941367
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03941548
Drug: CTP-543 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as tablets to aid treatment masking.
Study: NCT02081963
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
Study: NCT02081963
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
Study: NCT00262405
Drug: azathioprine/prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00440323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
Study: NCT00861185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
Study: NCT01065935
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by nebulization once daily for 5 days
Study: NCT03619213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching dapagliflozin 10 mg
Study: NCT00274391
Drug: 7% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00274391
Drug: Amiloride HCl
Normalized name: amiloride HCl
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00340431
Drug: MSP1(42)-FVO & MSP1(42)-3D7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00994617
Drug: Hydrochlorothiazide switched over with Losartan at 8 weeks
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
Study: NCT00811252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules; daily; orally
Study: NCT00592683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02651610
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
Study: NCT01854177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00787007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, oral, single dose
Study: NCT01476930
Drug: conventional migraine drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
Study: NCT02904226
Drug: JTX-2011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00296322
Drug: cisplatin, mitomycin-C, doxifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
Study: NCT02152969
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00443508
Drug: adding Certican to therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00446030
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
Study: NCT00446030
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
Study: NCT02635230
Drug: Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02420457
Drug: Epidural steroid injection as determined by routine care provider
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
Study: NCT04372264
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
Study: NCT00982566
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
Study: NCT00982566
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
Study: NCT00982566
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
Study: NCT01473524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets were administered orally once daily.
Study: NCT02473406
Drug: Thymosin Alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
Study: NCT02473406
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
Study: NCT00269763
Drug: Fentanyl Transdermal Therapeutic System (TTS)
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00699790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0mg, once daily, 12 weeks
Study: NCT03717740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
Study: NCT01358383
Drug: naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg, oral dose
Study: NCT01243931
Drug: OCT-guided laser phototherapeutic keratectomy
Normalized name: Urimar Reformulated Oct 2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
Study: NCT04073615
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets
Study: NCT03693872
Drug: Dopaminergic Agonist + Apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
Study: NCT00668005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01733329
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
Study: NCT00482001
Drug: Placebo (cornstarch)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02956655
Drug: Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
Study: NCT04032366
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: using of inhaled nitric oxide
Study: NCT03238924
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline nasal spray, self-administered
Study: NCT00780403
Drug: Zyrtec® (cetirizine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
Study: NCT01171118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
Study: NCT02119819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01302275
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Study: NCT03269318
Drug: Montelukast or Salmeterol or Theophylline or Steroid
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
Study: NCT02604966
Drug: DHA - PPQ group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
Study: NCT02732951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01826214
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
Study: NCT04030195
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
Study: NCT02463942
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
Study: NCT02463942
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
Study: NCT02455115
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
Study: NCT02455115
Drug: Chromium ethylenediaminetetraacetic acid
Normalized name: ethylenediaminetetraacetate
DrugBank: Edetic acid (DB00974)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extraction of 51Cr-EDTA measured for FF and GFR
Study: NCT00654927
Drug: Fampridine-SR b.i.d. (Twice Daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form - tablets.
Study: NCT03645187
Drug: FOLFERI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFERI regimen
Study: NCT03645187
Drug: Folferi and celecoxib
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folferi regimen and celecoxib
Study: NCT03916068
Drug: Trental Pill
Normalized name: Trental Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
Study: NCT01543490
Drug: ISV-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone in DuraSite® 2 twice daily for 2 weeks
Study: NCT03018015
Drug: Ibuprofen 400 mg oral powder
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03018015
Drug: Ibuprofen 400 mg film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03018015
Drug: Ibuprofen 400 mg soft capsule
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01024244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered po BID, prior to morning and evening meals for 12 weeks.
Study: NCT01609933
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-267 (tablets)
Study: NCT03340350
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline capsule
Study: NCT01902017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg placebo PO bid
Study: NCT02256111
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00716521
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose placebo
Study: NCT01587963
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
Study: NCT01976143
Drug: NKTR-102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01922843
Drug: DP001 softgel capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02347358
Drug: IV r-tPA
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous recombinant human tissue plasminogen activator
Study: NCT01557010
Drug: DWP05195
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral administration, 100mg
Study: NCT01557010
Drug: DWP05195
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral administration, 200mg
Study: NCT01557010
Drug: DWP05195
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, oral administration, 300mg
Study: NCT02373930
Drug: DTG 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
Study: NCT02373930
Drug: RPV 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
Study: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
Study: NCT02373930
Drug: DTG/RPV 50 mg/25 mg: Product Code AM
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally